Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Blood

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V92.5.1471.417K39_1471_1490PMID 9716573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessment and characterization of the cytolytic T lymphocyte response against Epstein–Barr virus in patients with non-Hodgkin’s lymphoma after autologous peripheral blood stem cell transplantation

  1998cited by this paper
• Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants

  1997cited by this paper
• Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion

  1997cited by this paper
• Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells

  1997cited by this paper
• Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.

  1997cited by this paper
• Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

  1997cited by this paper
• HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

  1997cited by this paper
• Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.

  1997cited by this paper
• Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation

  1997cited by this paper
• A comparison of gene transfer methods in human dendritic cells.

  1997cited by this paper
• Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

  1997cited by this paper
• Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells.

  1997cited by this paper
• Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide.

  1997cited by this paper
• Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants.

  1997cited by this paper
• Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.

  1997cited by this paper
• Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy.

  1997cited by this paper
• B cell development and differentiation.

  1997cited by this paper
• Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.

  1997cited by this paper
• Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study

  1997cited by this paper
• Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination

  1997cited by this paper
• The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.

  1997cited by this paper
• The treatment of relapsed or refractory intermediate grade non-Hodgkin’s lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon

  1997cited by this paper
• Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells.

  1997cited by this paper
• Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow

  1997cited by this paper
• Cellular immunotherapy and autologous transplantation for hematologic malignancy

  1997cited by this paper
• Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes

  1997cited by this paper
• Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

  1997cited by this paper
• Peripheral blood mononuclear cells from autologous hematopoietic stem cell transplantation recipients produce and respond to IL-12.

  1996cited by this paper
• Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.

  1996cited by this paper
• Induction of antitumor immunity using bone marrow-generated dendritic cells.

  1996cited by this paper
• Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: lack of somatic mutation indicates a maturational arrest.

  1996cited by this paper
• Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow.

  1996cited by this paper
• Erratum: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value (Proceedings of the National Academy of Science of the USA (February 6, 1996) 93 (1093-1096))

  1996cited by this paper
• Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

  1996cited by this paper
• Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

  1996cited by this paper
• Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).

  1996cited by this paper
• Interleukin-2 therapy: a decade of slow but steady progress.

  1996cited by this paper
• Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.

  1996cited by this paper
• Generation of antigen‐presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients

  1996cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7.

  1996cited by this paper
• Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

  1996cited by this paper
• Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation.

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996influential reference
• Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.

  1996cited by this paper
• Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts.

  1996cited by this paper
• Specific human cellular immunity to bcr-abl oncogene-derived peptides.

  1996cited by this paper
• Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing.

  1996cited by this paper
• Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation.

  1996cited by this paper
• Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.

  1996cited by this paper
• Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients.

  1996cited by this paper
• Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice.

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.

  1996cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper
• Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

  1996cited by this paper
• Time course of interferon-gamma production deficiency after autologous and allogeneic stem cell transplantation for malignancies.

  1995cited by this paper
• Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

  1995cited by this paper
• Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells

  1995cited by this paper
• Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha.

  1995cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995influential reference
• Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

  1995cited by this paper
• Extrathymic maturation of alpha beta T cells from hemopoietic stem cells.

  1995cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

  1995cited by this paper
• Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

  1995cited by this paper
• Activated T cells induce interleukin‐12 production by monocytes via CD40‐CD40 ligand interaction

  1995cited by this paper
• Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood.

  1995cited by this paper
• Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine

  1995cited by this paper
• Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.

  1995cited by this paper
• Extrathymic T cell differentiation.

  1995cited by this paper
• In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation.

  1995cited by this paper
• Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation.

  1995cited by this paper
• Alterations of T cell repertoire after bone marrow transplantation: characterization of over-represented subsets.

  1995cited by this paper
• Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.

  1995cited by this paper
• Recombinant human IL‐7 administration in mice affects colony‐forming units‐spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants

  1995cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

  1995cited by this paper
• Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin.

  1995cited by this paper
• Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.

  1995cited by this paper
• Cellular adoptive immunotherapy after bone marrow transplantation.

  1995cited by this paper
• Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.

  1995cited by this paper
• Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

  1995cited by this paper
• Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.

  1995cited by this paper
• T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life.

  1995cited by this paper
• Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group.

  1995cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

  1995cited by this paper
• Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation.

  1994cited by this paper
• Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.

  1994cited by this paper
• The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.

  1994cited by this paper
• Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo

  1994cited by this paper
• Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice

  1994cited by this paper
• Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

  1994cited by this paper
• Influenza A virus infections among hospitalized adult bone marrow transplant recipients.

  1994cited by this paper
• In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

  1994cited by this paper
• A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

  1994cited by this paper
• Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation.

  1994cited by this paper
• Expansion and activation of human natural killer cells as therapy for autologous transplantation.

  1994cited by this paper
• Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.

  1994cited by this paper

• Next-generation sequencing protocol of hematopoietic stem cells (HSCs). Step-by-step overview and troubleshooting guide

  2025cites this paper
• T cell subgroup analysis and T cell exhaustion after autologous stem cell transplantation in lymphoma patients.

  2025cites this paper
• Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

  2024cites this paper
• Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis.

  2024cites this paper
• MicroRNA Profiles in Hematopoietic Stem Cell Transplant Recipients

  2024cites this paper
• The shifting roles and toxicities of cellular therapies in B‐cell malignancies

  2023influential citation
• Atypical haemolytic uremic syndrome with refractory multiorgan involvement and heterozygous CFHR1/CFHR3 gene deletion

  2023cites this paper
• Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea

  2023cites this paper
• Enrichment of effector memory T cells in the CD4 and CD8 T cell compartment during chronic graft versus host disease in children.

  2023cites this paper
• CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

  2023cites this paper
• Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?

  2023cites this paper
• Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

  2022cites this paper
• In vivo observation of multi‐phase spatiotemporal cellular dynamics of transplanted HSPCs during early engraftment

  2022cites this paper
• Lymphopenia and Mechanisms of T-Cell Regeneration

  2022influential citation
• Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.

  2022cites this paper
• Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT

  2022cites this paper
• Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation

  2021cites this paper
• Hematopoietic Stem Cell Requirement for Macrophage Regeneration Is Tissue Specific

  2021cites this paper
• Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?

  2021cites this paper
• Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience

  2020cites this paper
• Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation

  2020cites this paper
• Cellular Therapy

  2020influential citation
• Dynamical properties of feedback signalling in B lymphopoiesis: A mathematical modelling approach.

  2020cites this paper
• The monocyte system in haematological malignancies

  2020cites this paper
• Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.

  2020cites this paper
• Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation

  2020cites this paper
• Aspects of Phagocyte Function in Multiple Myeloma

  2019cites this paper
• Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation

  2019cites this paper
• A lymphoma patient with Cytomegalovirus retinitis and post‐autologous hematopoietic cell transplantation immune reconstitution uveitis: A case report and review of the literature

  2019cites this paper
• Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

  2019cites this paper
• Profound but transient changes in the inflammatory milieu of the blood during autologous hematopoietic stem cell transplantation.

  2019cites this paper
• Hematologic Malignancies

  2019cites this paper
• Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment.

  2019cites this paper
• Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist

  2018influential citation
• Immune Reconstitution After Hematopoietic Stem Cell Transplantation

  2018cites this paper
• Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice.

  2018cites this paper
• Maintenance and continuous therapy for multiple myeloma

  2018influential citation
• Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

  2018cites this paper
• Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors

  2017cites this paper
• HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma

  2017cites this paper
• The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.

  2017cites this paper
• Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

  2017cites this paper
• Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy

  2017cites this paper
• The multi-faceted potential of CD38 antibody targeting in multiple myeloma

  2017cites this paper
• A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma

  2017cites this paper
• Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

  2017cites this paper
• This information is current as Granulocyte Colony-Stimulating Factor High-Dose Cyclophosphamide and in Stem Cell Autografts by Mobilization with Functional Regulatory T Cells Are Collected

  2017cites this paper
• Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies

  2016cites this paper
• Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice

  2016cites this paper
• TARGETING PD-1/PDL-1 SIGNALING IN THE TREATMENT OF OSTEOSARCOMA LUNG METASTASIS

  2016cites this paper
• Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children.

  2016cites this paper
• Homeostatic cytokines in immune reconstitution and graft-versus-host disease.

  2016cites this paper
• Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases.

  2016cites this paper
• Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma

  2016cites this paper
• Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

  2016cites this paper
• Immune reconstitution and vaccination following hematopoietic cell transplantation

  2016cites this paper
• Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.

  2016cites this paper
• Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

  2016cites this paper
• Targeting Immune Checkpoints in Hematologic Malignancies

  2016cites this paper
• Toxoplasmosis Gondii Infection and Diabetes Mellitus Type 2 Treated by Using Autologous Peripheral Blood Stem Cells a Unique Case Report of a Caucasian 83 Year Old Lady

  2015cites this paper
• Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.

  2015cites this paper
• Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia

  2015cites this paper
• Tumor-Specific CD4 Efficacy of Adoptive Immunotherapy Using Alkylating Agent Melphalan Augments the

  2015cites this paper
• Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System

  2015cites this paper
• Mechanisms of blood homeostasis: lineage tracking and a neutral model of cell populations in rhesus macaques

  2015cites this paper
• Design and methods

  2015cites this paper
• Induction of tolerance and prolongation of islet allograft survival by syngeneic hematopoietic stem cell transplantation in mice.

  2015cites this paper
• Autologous Peripheral Blood Stem Cells and γ / δ T Cells May Improve Immunity in Treating Secondary Bacteremic Infection in HIV Infected Patient

  2015influential citation
• Immune checkpoint blockade in hematologic malignancies.

  2015cites this paper
• Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma

  2015cites this paper
• NK cells and exercise: implications for cancer immunotherapy and survivorship.

  2015cites this paper
• Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

  2015cites this paper
• Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+ T Cells

  2015cites this paper
• Myc and AP-1 expression in T cells and T-cell activation in patients after hematopoietic stem cell transplantation

  2015cites this paper
• Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

  2015cites this paper
• Upregulated heme oxygenase‐1 expression of mouse mesenchymal stem cells resists to chemotherapy‐induced bone marrow suppression

  2014cites this paper
• Epigenetics and Cyclooxygenase-2 Mediate Dysfunction in Alveolar Macrophages and Polymorphonuclear Neutrophils Post-bone Marrow Transplantation.

  2014cites this paper
• Successful Transplantation of Kidney Allografts in Sensitized Rats After Syngeneic Hematopoietic Stem Cell Transplantation and Fludarabine

  2014cites this paper
• Phenotype and functionality of pathogen specific T cells in chronic infections and implications for novel diagnostic and therapeutic approaches

  2014cites this paper
• Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation.

  2014cites this paper
• Pleurisy as a novel clinical manifestation associated with human herpesvirus 6 after unrelated cord blood transplantation

  2014cites this paper
• A review of pathogens causing lower respiratory tract infection in the pediatric hematopoietic stem cell transplant recipient

  2014cites this paper
• Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

  2013cites this paper
• Early cell-cycle gene expression in T-cells after hematopoietic stem cell transplantation.

  2013cites this paper
• potential for generating B cells with a diverse immunoglobulin repertoire Human fetal, cord blood, and adult lymphocyte progenitors have similar

  2013cites this paper
• Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors

  2013cites this paper
• expansion after BMT immunity from T-cell populations undergoing homeostatic peripheral oligodeoxynucleotides and IL-2 generate antigen-specific antitumor Vaccination regimens incorporating CpG-containing

  2013cites this paper
• Disseminated toxoplasmosis in non-allografted patients with hematologic malignancies: report of two cases and literature review

  2013cites this paper
• Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.

  2013cites this paper
• T‐cell responses after haematopoietic stem cell transplantation for aggressive relapsing–remitting multiple sclerosis

  2013cites this paper
• Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies

  2013cites this paper
• naive and memory populations depleting therapy affecting - Defective T-helper cell function after T-cell

  2013cites this paper
• lymphoma hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin Early lymphocyte recovery predicts superior survival after autologous

  2013cites this paper
• Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

  2013influential citation
• CsA 2-h concentration correlates best with area under the concentration–time curve after allo-SCT compared with trough CsA

  2012cites this paper
• A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.

  2012cites this paper
• Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

  2012influential citation
• COX-2 Expression Is Upregulated by DNA Hypomethylation after Hematopoietic Stem Cell Transplantation

  2012cites this paper
• Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy.

  2012cites this paper
• Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma.

  2012cites this paper